SCTX 8-K
Scribe Therapeutics, Inc. (SCTX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On September 2, 2026, Scribe Therapeutics Inc. (the "Company") announced its financial results for the quarter ended June 30, 2026 and provided a business update. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit number |
Description |
99.1 |
Earnings Press Release Issued by Scribe Therapeutics Inc on September 02, 2026. |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 2, 2026 |
|
By: |
/s/ Benjamin L. Oakes |
|
|
|
Benjamin L. Oakes, Ph.D. |
|
|
|
Chief Executive Officer (Principal Executive Officer) |
Pipeline Highlights
STX-1150: In vivo epigenetic silencing therapy for LDL-C lowering
STX-1200 and STX-1400: Advancing cardiometabolic gene editing programs targeting genetically driven, severely elevated Lp(a) and triglycerides, respectively. Awarded approximately $25.7 million in combined non-dilutive CIRM grants.
Platform and Scientific Leadership
Published updated findings in bioRxiv, highlighting the ELXR platform's novel enhancements in potency and safety enabling the durable repression of target genes without permanent DNA modification.
Corporate Highlights
Second Quarter 2026 Financial Results
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe’s strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe’s product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, STX-1400 and other programs; the expected use and benefits of CIRM funding; and Scribe’s expected cash runway and financial position are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those described under the heading “Risk Factors” in Scribe’s filings with the U.S. Securities and Exchange Commission, including its final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events.
Investor Contact:
Investor Relations, Scribe Therapeutics
Media Contact:
Thermal for Scribe Therapeutics
SCRIBE THERAPEUTICS INC. |
Statement of Operations |
(in thousands, except share and per share data) |
(Unaudited) |
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Collaboration revenue |
|
$ |
1,918 |
|
|
$ |
4,898 |
|
|
$ |
4,151 |
|
|
$ |
22,023 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
8,823 |
|
|
|
13,884 |
|
|
|
20,128 |
|
|
|
29,876 |
|
General and administrative |
|
|
2,490 |
|
|
|
2,641 |
|
|
|
5,844 |
|
|
|
9,332 |
|
Total operating expenses |
|
|
11,313 |
|
|
|
16,525 |
|
|
|
25,972 |
|
|
|
39,208 |
|
Loss from operations |
|
|
(9,395 |
) |
|
|
(11,627 |
) |
|
|
(21,821 |
) |
|
|
(17,185 |
) |
Interest income and other income (expense), net |
|
|
383 |
|
|
|
880 |
|
|
|
898 |
|
|
|
1,944 |
|
Interest expense |
|
|
(276 |
) |
|
|
(598 |
) |
|
|
(875 |
) |
|
|
(1,197 |
) |
Change in fair value of Convertible Note |
|
|
3,023 |
|
|
|
730 |
|
|
|
(1,585 |
) |
|
|
2,083 |
|
Net loss before provision for income taxes |
|
|
(6,265 |
) |
|
|
(10,615 |
) |
|
|
(23,383 |
) |
|
|
(14,355 |
) |
(Provision for) / benefit from income tax |
|
|
(212 |
) |
|
|
712 |
|
|
|
(441 |
) |
|
|
1,027 |
|
Net loss |
|
$ |
(6,477 |
) |
|
$ |
(9,903 |
) |
|
$ |
(23,824 |
) |
|
$ |
(13,328 |
) |
SCRIBE THERAPEUTICS INC. |
Selected Balance Sheet Items |
(in thousands, except share and per share data) |
(Unaudited) |
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
|
|
(in thousands) |
|
|||||
Cash, cash equivalents and investments |
|
$ |
43,009 |
|
|
$ |
57,963 |
|
Total Assets |
|
|
57,927 |
|
|
|
78,219 |
|
Total Liabilities |
|
|
102,417 |
|
|
|
101,282 |
|
Total stockholders' deficit |
|
$ |
(164,846 |
) |
|
$ |
(143,419 |
) |